Trial Profile
A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Preliminary Anti-tumour Activity of Ascending Doses of Selumetinib (AZD6244 Hyd-sulfate) in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Selumetinib (Primary) ; Tremelimumab
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms SELECT-4
- Sponsors AstraZeneca
- 15 Nov 2019 Status changed from active, no longer recruiting to completed.
- 07 Nov 2018 Planned End Date changed from 10 Jul 2018 to 31 Dec 2019.
- 23 Feb 2018 Planned End Date changed from 5 Oct 2018 to 10 Jul 2018.